

Nosocomial Burn Wound Infections due to Non-Fermenting Gram Negative Bacteria: Our Experiences From A Tertiary Care Center In North India

Naz Perween¹, S. Krishna Prakash², Prabhav Aggarwal^{2*} and Lalit Mohan Gupta²

¹Dept. of Microbiology, Superspeciality Pediatric Hospital and Postgraduate Teaching Institute, NOIDA, India

²Dept. of Microbiology, Maulana Azad Medical College, New Delhi, India

Keywords: *Pseudomonas*, *Acinetobacter*, Antimicrobial Resistance, Burns.

ABSTRACT

Background: Nosocomial infections contribute to up to 50% mortality in burn patients. Non fermenting Gram negative bacteria, being ubiquitous in nature, can easily colonize the burn site and subsequently cause infections. The objective of the study was to understand the role of two of the most common non-fermenters, *Pseudomonas aeruginosa* and *Acinetobacter baumannii* in nosocomial burn wound infections and determine their antimicrobial resistance pattern.

Methods: Wound swabs were collected from burn patients and cultured using standard microbiological techniques. Isolates of non-fermenters, *Pseudomonas aeruginosa* and *Acinetobacter baumannii*, were identified by conventional biochemical tests. The antibiotic susceptibility testing of these isolates were carried out by disc diffusion method.

Result: A total of 248 and 70 clinical strains of *Pseudomonas aeruginosa* and *Acinetobacter baumannii* were isolated, respectively. Out of these, 67.62% and 72.05% isolates of *Pseudomonas aeruginosa* and *Acinetobacter baumannii* were MDR. *Pseudomonas* showed highest resistance to gentamicin (83.3%), followed by ceftazidime (80.18%), and Netilmicin (76.89%). Among *Acinetobacter baumannii* isolates, resistance to cephalexin (98.5%) was highest, followed by gentamicin (94.6%) and cefotaxime (94.12%).

Conclusion: The increasing antibiotic resistance shown by these important pathogens leaves us with fewer option to treat severe life-threatening infections, stressing the need of a continuous antibiotic surveillance program and stringent implementation of infection control practices.

***Corresponding author:**

Dr Prabhav Aggarwal, E-49, Sector-55, NOIDA, Uttar Pradesh-201301, India

Phone: +91 9899303626

Email: prabhavaggarwal@yahoo.co.in



Introduction

Infections are an important cause of morbidity and mortality in patients with burns. Wound infections are one of the most common sites of nosocomial infections in burn patients with prevalence of about 60%, followed by blood stream infections (20%), urinary tract infections (20%) and pneumonia (10%).^[1] Burn wound infections can lead to scarring, bacteremia, sepsis and multi-organ dysfunction, contributing to 75% mortality in burn patients.^[2,3] The occurrence of nosocomial burn infections depends on several factors such as the burn severity, immune status, prolonged stay, invasive procedures and overcrowding leading to cross infections.^[4]

Disruption of skin and vasculature with resulting compromise in the immune status is the usual pathogenesis.^[5,6] Hence the infected burn wound is a frequent source of sepsis.^[3] *Pseudomonas aeruginosa*, *Acinetobacter*, *Staphylococcus aureus*, *Klebsiella spp.* and other Gram negative bacteria are commonly incriminated pathogens in burn patients.^[1]

Pseudomonas aeruginosa is known to frequently colonize the inanimate surfaces like floors, bed rails, sinks in the hospital and is transmitted by hands of health care workers.^[7] Its resistance to commonly used disinfectants and antibiotics are the contributing factors. Hence, *Pseudomonas* infection is challenging to treat and is associated with a high mortality rate.^[8]

Acinetobacter baumannii is also rapidly emerging nosocomial pathogen in various countries including India, especially in ICUs, burn units and surgical wards.^[4] Like *Pseudomonas*, *Acinetobacter baumannii* tends to exist in the hospital environment due to its ability to adhere on inanimate surfaces and is also inherently resistant to several antibiotics. Hence, this species is notorious for causing infections where there is a breach in natural immunity like in the burn wounds.^[9]

Burn units are often the sites of major and prolonged outbreaks with resistant organisms.¹⁰ Both *Pseudomonas aeruginosa* and *Acinetobacter baumannii* can be problematic due to their inherent resistance to several drug classes as well as the easy development of acquired resistance.^[5] Multidrug resistant *Pseudomonas aeruginosa* (MDR Pa) in burn units is often associated with significant morbidity and mortality; mostly due to lack of treatment options.^[7] Previous studies reveal the fact that the bacterial profile of burn wound infections changes over time in any given burn unit probably due to cross infections, change in antibiotic use, and overcrowding.^[11] Hence, it is important to regularly monitor the bacterial species responsible for burn wound infections and their antibiotic susceptibility pattern, to aid

use of appropriate antibiotics both for empirical therapy and specific treatment.

Thus, the present study was conducted to determine the role of non-fermenting Gram negative bacteria, namely *Pseudomonas aeruginosa* and *Acinetobacter baumannii* in the burn wound infection and assess their prevalent antibiotic susceptibility pattern.

Materials And Methods

The study included 1294 burn wound patients admitted in the burns unit of a 1600-bedded tertiary care hospital in New Delhi, India during the year 2012. Swabs and/or pus discharge were collected from the apparently infected site after decontaminating the wound. The swabs/pus were inoculated onto blood agar and MacConkey's agar. In addition, pus specimen was inoculated in Brain Heart infusion broth and incubated for 24hrs at 37°C; subsequent subculture was done on blood agar and MacConkey's agar if primary plates failed to show bacterial growth. The plates were incubated at 37°C for 24-48 hours in ambient air. The identification of *Pseudomonas aeruginosa* and *Acinetobacter baumannii* was done using the standard biochemical tests. The antibiotic susceptibility testing was carried out by the modified Stokes disc diffusion method against gentamicin, amikacin, ciprofloxacin, piperacillin/tazobactam, imipenem, meropenem, netilmicin, polymixin B and colistin. *Pseudomonas aeruginosa* isolates were also tested against aztreonam, ceftazidime and tobramycin; and *Acinetobacter baumannii* was also tested against cephalixin, cefotaxime, ceftriaxone and amoxicillin (HiMedia Ltd., India).

Pseudomonas aeruginosa isolates were identified as MDR Pa (Multi-drug resistant *Pseudomonas aeruginosa*), if the isolate was resistant to drug(s) in three or more antimicrobial classes; XDR Pa (Extensively drug resistant *Pseudomonas aeruginosa*) when resistant to all tested antibiotics except one or two classes; and PDR Pa (Pan drug resistant *Pseudomonas aeruginosa*) when resistant to all drug classes.^[12] MDR *Acinetobacter spp.* was defined as the isolate resistant to at least three classes of antimicrobial agents: all penicillins and cephalosporins (including inhibitor combinations), fluoroquinolones, and aminoglycosides; XDR (Extensively drug resistant) *Acinetobacter spp.* was defined as isolate that was resistant to the three classes of antimicrobials described above (MDR) and also to carbapenems; and PDR (Pan drug resistant) *Acinetobacter spp.* was the XDR *Acinetobacter spp.* that was also resistant to polymyxins and tigecycline.^[13]

Result

Wound swabs/ pus specimens were collected from the infected wound sites of 1,294 patients and transported

to the Microbiology laboratory immediately. The study population included 711 males and 583 females with male: female ratio of 1.22. The median age of these patients was 32 years (range=11–76 years).

On culture, 171 specimens showed no growth; while rest of the wound swabs had bacterial growth, including 160 samples with poly-microbial growth; yielding a total of 883 bacterial isolates. These included 248 (28.08%) isolates of *Pseudomonas aeruginosa* and 70 (7.92%) of *Acinetobacter baumannii*. Therefore, the non fermenting Gram negative bacteria constituted 36% (318/883) of the total isolates. Gram positive cocci constituted 15.96% (141/883) of the isolates, while 47.88% (424/883) were members of Family Enterobacteriaceae.

Pseudomonas isolates showed highest resistance towards gentamicin (83.33%) followed by ceftazidime, netilmicin (Table 1). Most of the *Acinetobacter* isolates were highly resistant to amoxicillin, cephalexin, ceftriaxone and cefotaxime, (100%, 98.51%, 90.91% and 94.12% respectively). Approximately, 50% and 16% of the isolates were resistant to imipenem and Meropenem, respectively (Table 2).

We found that 67.62% *Pseudomonas* and 72.05% *Acinetobacter* isolates were multidrug resistant (MDR); while approximately 17% strains of both *Pseudomonas* and *Acinetobacter* isolates were extensively drug resistant (XDR). None of *Pseudomonas* or *Acinetobacter* strains were Pan drug resistant (PDR) (Table 3).

Table 1: Antimicrobial susceptibility pattern of *Pseudomonas aeruginosa*.

Antimicrobial agent	Susceptible (%)	Intermediate susceptible (%)	Resistant (%)
Ceftazidime	16.13	3.69	80.18
Piperacillin + Tazobactam	65.82	18.99	15.19
Aztreonam	30.77	9.62	59.62
Imipenem	85.25	5.74	9.02
Meropenem	70.42	10.83	18.75
Ciprofloxacin	25.16	3.87	70.97
Gentamicin	16.22	0.44	83.33
Amikacin	25	8.97	66.03
Netilmicin	21.23	1.89	76.89
Tobramycin	17.84	4.87	77.29
Polymyxin B	93.78	1.91	4.31
Colistin	92.13	2.81	5.06

Table 2: Antibiotic susceptibility pattern of *Acinetobacter baumannii*.

Antimicrobial agent	Susceptible (%)	Intermediate susceptible (%)	Resistant (%)
Amoxicillin	0	0	100
Cephalexin	1.49	0	98.51
Ceftriaxone	0	9.09	90.91
Cefotaxime	0	6.25	94.12
Piperacillin/tazobactam	37.5	27.5	35
Imipenem	37.14	14.29	48.57
Meropenem	47.37	36.84	15.79
Ciprofloxacin	17.14	5.71	77.14
Gentamicin	5.41	0	94.6
Amikacin	6.45	4.84	88.71
Netilmicin	32.35	9.52	61.76
Polymyxin B	92	0	8
Colistin	84.85	0	15.15

Table 3: Patterns of drug resistance in isolates of *Pseudomonas* and *Acinetobacter*.

Drug resistance	<i>Pseudomonas aeruginosa</i> (n= 244)	<i>Acinetobacter baumannii</i> (n=68)
MDR	165 (67.62)	49 (72.05)
XDR	41 (16.80)	12 (17.64)
PDR	0 (0)	0 (0)

Note: MDR: multidrug resistant; XDR: extensively drug resistant; PDR: Pan drug resistant Figures in parentheses indicate percentages.

Discussion

The prevalence of non-fermenting Gram negative bacteria in our study, namely *Pseudomonas aeruginosa* and *Acinetobacter baumannii* was found to be 28.8% and 7.92%, respectively. Few other Indian studies involving burns patients have shown wide isolation rates of *Pseudomonas aeruginosa* ranging from 18.2 to 59%, as well as that of *Acinetobacter baumannii* ranging from 7.2-28.6% (Table 4). Our result is comparable to the Tamil Nadu based study done in 2011 where the prevalence of *Pseudomonas aeruginosa* in burn wound infections was 28%;^[16] however, *Acinetobacter* was not isolated in that study. Results of the previous studies from Varanasi, Mumbai and Delhi corroborate with our findings.^[3,17,20]

However, global studies report slightly higher isolation rate of *Pseudomonas aeruginosa* and *Acinetobacter baumannii* as compared to those reported by Indian authors, with the

isolation rates ranging from 28-58.3% and 10.4-62.3% respectively (Table 5). In western countries, *Pseudomonas aeruginosa* is found to be the most prevalent cause of burn wound infection followed by *Acinetobacter*.

In our study, *Pseudomonas aeruginosa* isolates showed high resistance to resistant to gentamicin (83.33%). Previous studies done in Turkey and Baghdad revealed the lower resistance to gentamicin (40% and 45% respectively).^[5,22] However, in Iran 100% sensitivity to gentamicin was seen.^[11] Resistance to amikacin in our study was again much higher than reported in other studies done elsewhere in India, where majority of the isolates were sensitive.^[3,15] International studies too revealed a much lower resistance rate, except in the Baghdad based study where the amikacin resistance rate was 84.6%.^[13] High resistance was also seen towards netilmicin, tobramycin and ciprofloxacin (76.89%, 77.29% and 70.97%, respectively). This is in contrast to the studies

TABLE 4: Indian scenario of the role of *Pseudomonas* and *Acinetobacter* in burn wound infection cases.

Place of study	Author	Period of study	<i>Pseudomonas</i> spp. (%)	<i>Acinetobacter</i> spp.
Pune ¹⁴	Bhatt P <i>et al</i>	2013-14	54.9	18.6
Karnataka ¹⁵	Bhat AS <i>et al</i>	2013	18.2	28.6
TN ¹⁶	Valarmathi S <i>et al</i>	2011	28	-
Mumbai ³	Srinivasan S <i>et al</i>	1994-2006	31.84	-
Chandigarh ⁴	Mehta M <i>et al</i>	2002-05	51.5	14.23
Varanasi ¹⁷	Anupurba S <i>et al</i>	2004-05	32	-
Chandigarh ¹⁸	Agnihotri N <i>et al</i>	1997-2002	59	7.2
Delhi ¹⁹	Sharma S <i>et al</i>	1992-1994	53.9	-
Delhi ²⁰	Singh NP <i>et al</i>	1997-2002	31	-
Delhi ²¹	Revathi G <i>et al</i>	1993-97	36	1.1

TABLE 5 International scenario of the role of *Pseudomonas* and *Acinetobacter* in burn wound infections cases.

Place of study	Author	Period of study	<i>Pseudomonas</i> spp. (%)	<i>Acinetobacter</i> spp. (%)
Turkey ²²	Yolbaş I <i>et al</i>	2008-09	25.8	62.3
USA ²³	Keen EF <i>et al</i>	2003-08	20.04	22.2
Baghdad ²	Alkaabi SAG	2011-11	48.14	14.81
Iran ¹	Ekrami A	2003-04	37.5	10.4
Turkey ¹⁰	Oncul O <i>et al</i>	2004-05	57	21
Iran ²⁴	Azimi L <i>et al</i>	2010	40	17
Baghdad ⁵	Hussien IA <i>et al</i>	2010-11	58.3	-

done in Iran and Baghdad, which showed 0% and 34.3% resistance against tobramycin.^[1,5] The resistance rate for ciprofloxacin in our study was much higher as compared to a Karnataka based study where most of the isolates (95.8%) were sensitive.^[15] Similarly, in Turkey and Baghdad, 22.8-29% resistance was seen.^[5,22] However, as the resistance pattern differs among different institutions, another study in Baghdad revealed 84.6% of ciprofloxacin resistance.^[2]

In our study, resistance to ceftazidime was 80.18%, higher as compared to the studies done in abroad, where the resistance of 55-60.25% has been reported.^[2,5] Resistance against rest of the antibiotics, imipenem, meropenem, piperacillin + tazobactam, polymyxin B and colistin was lower, though still comparable to most of the international studies.^[1,7,10,22]

The resistance to gentamicin in *Acinetobacter baumannii* isolates in our study was 94.6%, as against 55.6% and 96% in studies done abroad.^[9,23] An Iranian study revealed 100% sensitivity of *Acinetobacter* to this drug.^[1] Other drugs against which high resistance was shown by *Acinetobacter* were amikacin (88.71%), ciprofloxacin (77.14%), ceftriaxone (90.91%), cephalexin (98.51%), amoxicillin (100%), and netilmicin (61.76%) while the rest of the antibiotics were relatively more effective. Resistance to amikacin, ciprofloxacin and ceftriaxone was also high in other studies, similar to ours.^[2,9,22] Amoxicillin resistance reported from Vietnam and Baghdad was also 100%, similar to our study.^[2,9]

Although there is no consensus regarding the definition of the terms 'multidrug resistant', 'extensively drug resistant' and 'pan drug resistant' used for these bacteria, we used the previously described and commonly used definitions to report the results of our study.^[12,13] Approximately two-thirds of the *Pseudomonas* strains and three-fourths of the *Acinetobacter baumannii* strains were resistant to three or more anti-microbial classes defined for each bacteria, making them MDR. Seventeen percent strains of both showed extensive drug resistance. Pan drug resistance was not seen in our study. A USA based study had reported MDR Pa as 15% and MDR *Acinetobacter* as high as 53%; while there was only 1 isolate each of Pan DR Pa and Pan DR *Acinetobacter*.^[23] A Turkish study has previously shown 7.7% and 13.2% pan drug resistance in these isolates from burn wound infections.^[10] These are much low as compared to our study; however, comparison with these studies may not be accurate due to lack of standard definitions for these terminologies; thus emphasizing the urgent need for clear-cut definitions.

Conclusion

To conclude, burns units in every hospital should determine the bacterial profile of the burn wounds and the antibiotic

susceptibility pattern at regular intervals, and should also study the trend in the nosocomial spread of the pathogens. This will guide in the administration of empirical antibiotic therapy before the culture results are obtained. There should be a strict infection control policy in place with a stringent antibiotic stewardship program in order to ensure optimum treatment of the patient and to curb the menace of antibiotic resistant organisms. In addition, clear definitions of Multi drug resistance, Extensive drug resistance and Pan drug resistance should be available, to optimize inter-study comparisons.

Acknowledgements

None

Funding

None

Competing Interests

None Declared

References

1. Ekrami A, Kalantar E. Bacterial infections in burn patients at a burn hospital in Iran. *Indian J Med Res* 2007;126:541-4.
2. Alkaabi SAG. Bacterial Isolates and Their Antibiograms of Burn Wound Infections in Burns Specialist Hospital in Baghdad. *J Baghdad Sci* 2013;10(2):331-40.
3. Srinivasan S, Vartak AM, Patil A, Saldanha J. Bacteriology of the burn wound at the Bai Jarbai Wadia Hospital for children, Mumbai, India- A 13 year study, Part-I Bacteriological profile. *Indian J Plast Surg*. 2009;42(2):213-218.
4. Mehta M, Dutta P, Gupta V. Bacterial isolates from burn wound infections and their antibiograms: A eight year study. *Indian J Plast Surg*. 2007;40(1):25-8.
5. Hussien IA, Habib KA, Jassim KA. Bacterial Colonization of Burn Wounds. *J Baghdad Sci*. 2012;9(4):623-31.
6. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn Wound Infections. *Clin Microbiol Rev*. 2006;19(2):403-34.
7. Japoni A, Anvarinejad M, Farshad S, Giammanco GM, Rafaatpour N, Alipour E. Antibiotic Susceptibility Patterns and Molecular Epidemiology of Metallo- β -Lactamase Producing *Pseudomonas Aeruginosa* Strains Isolated from Burn Patients. *Iran Red Crescent Med J*. 2014;16(5):1-6.
8. Branski LK, Al-Mousawi A, Rivero H, Jeschke MG, Sanford AP, Herndon DN. Emerging Infections in Burns. *Surg Infect*. 2009;10(5):389-97.

9. Van TD, Dinh Q, Vu PD, Nguyen TV, Pham CV, Dao TT et al. Antibiotic susceptibility and molecular epidemiology of *Acinetobacter calcoaceticus-baumannii* complex strains isolated from a referral hospital in northern Vietnam. *J Glob Antimicrob Resist*. 2014;2(4):318-21.
10. Oncul O, Ulkur E, Acar A, Turhan V, Yeinz E, Karacaer Z, Yildiz F. Prospective analysis of nosocomial infections in a Burn Care Unit, Turkey. *Indian J Med Res*. 2009;130:758-64.
11. Liwimbi, OM, Komolafe IOO. Epidemiology and bacterial colonization of burn injuries in Blantyre. *Malawi Med J*. 2007;19(1):25-7.
12. Falagas ME, Karageorgopoulos DE. Pandrug Resistance (PDR), Extensive Drug Resistance (XDR), and Multidrug Resistance (MDR) among Gram-Negative Bacilli: Need for International Harmonization in Terminology. *Clin Infect Dis*. 2008;46(7):1121-2.
13. Manchanda V, Sanchaita S, Singh NP. Multidrug resistant *Acinetobacter*. *J Global Infect Dis*. 2010;2:291-304.
14. Bhatt P, Rathi KR, Hazra S, Sharma A, Shete V. Prevalence of multidrug resistant *Pseudomonas aeruginosa* infection in burn patients at a tertiary care centre. *Indian J Burns* 2015;23:56-9.
15. Bhat AS, Vinodkumar CS. Prevalence of burn wound infections with aerobic and anaerobic bacteria and their antimicrobial susceptibility pattern at tertiary care hospital. *Int J Sci Res*. 2013;2(11):410-3.
16. Valarmathi S, Pandian MR, Senthilkumar B. Incidence and screening of wound infection causing microorganisms. *J Acad Indus Res*. 2013;1(8):508-10.
17. Anupurba S, Bhattacharjee, A, Garg A, Sen MR. Antimicrobial susceptibility of *Pseudomonas aeruginosa* isolated from wound infections. *Indian J Dermatol*. 2006;51(4):286-8.
18. Agnihotri N, Gupta V, Joshi RM. Aerobic Bacterial Isolates from burn wound infections and their antibiograms- a five year study. *Burns*. 2004;30(3):241-3.
19. Sharma S, Hans C. Bacterial Infections in Burn patients: A three years study at RML Hospital, Delhi. *J Commun Dis*. 1996;28(2):101-6.
20. Singh NP, Goyal R, Manchanda V, Das S, Kaur I, Talwar V. Changing Trends in bacteriology of burns in burns unit, Delhi, India. *Burns*. 2003;29(2):129-32.
21. Revathi G, Puri J, Jain BK. Bacteriology of Burns. *Burns*. 1998;24(4):347-9.
22. Yolbaş I, Tekin R, Kelekçi S, Selçuk CT, Okur MH, Tan I, et al. Common pathogens isolated from burn wounds and their antibiotic resistance patterns. *Dicle Med J*. 2013;40(3):364-8.
23. Keen EF, Robinson BJ, Hospenthal DR, Aldous WK, Wolf SE, Chung KK, et al. Incidence and bacteriology of burn infections at a military burn center. *Burns*. 2010;36(6):461-8.
24. Azimi L, Motevallian A, Ebrahimzadeh Namvar A, Asghari B, Lari AR. Nosocomial Infections in Burned Patients in Motahari Hospital, Tehran, Iran. *Dermatol Res. Pract*. 2011; doi: 10.1155/2011/436952.